Canale D, Scaricabarozzi I, Giorgi P, Turchi P, Ducci M, Menchini-Fabris G F
Clinical Unit, University of Pisa Medical School and Hospital, Italy.
Andrologia. 1993 May-Jun;25(3):163-6. doi: 10.1111/j.1439-0272.1993.tb02701.x.
Nimesulide, a novel non-steroidal anti-inflammatory drug, was used in cases of abacterial prostato-vesiculitis. Thirty patients with a mean age of 33.7 years (range 18-58) were studied. Nimesulide was administered orally 100 mg b.i.d. for three cycles of 10 d each. Dysuric symptoms, semen analysis, and transrectal ultrasound were examined during the study. The concentration-time curves of nimesulide (NIM) and its metabolite, hydroxynimesulide (OH-NIM) in seminal fluid were also evaluated after single oral administration (100 mg) using an HPLC technique. Following administration of the drug, the Cmax was reached in seminal fluid at the second hour for NIM (with a mean value +/- SD of 0.58 +/- 0.13 micrograms ml-1) and at the fourth hour for OH-NIM (2.98 +/- 0.38 micrograms ml-1). Maximal seminal fluid concentrations compared to blood plasma levels were observed at the fourth hour for both substances (31.73 +/- 2.34% for NIM; 31.87 +/- 8.66% for OH-NIM. Dysuric symptoms were relieved in 20 (66%) patients. A clear amelioration of inflammatory signs were observed at transrectal ultrasound evaluation in 16 (54%) patients. No statistically significant changes of sperm count and motility in the whole sample were observed, while a significant reduction in the number of abnormal forms occurred. From these results, nimesulide appears to be an effective anti-inflammatory drug with a good diffusion into the genital apparatus and low side-effects.
尼美舒利是一种新型非甾体抗炎药,用于治疗非细菌性前列腺精囊炎。研究了30例平均年龄为33.7岁(范围18 - 58岁)的患者。尼美舒利口服给药,剂量为100mg,每日2次,共三个疗程,每个疗程10天。研究期间检查排尿困难症状、精液分析和经直肠超声。还使用高效液相色谱技术评估了单次口服给药(100mg)后尼美舒利(NIM)及其代谢产物羟基尼美舒利(OH - NIM)在精液中的浓度 - 时间曲线。给药后,精液中NIM在第2小时达到Cmax(平均值±标准差为0.58±0.13μg/ml),OH - NIM在第4小时达到Cmax(2.98±0.38μg/ml)。两种物质在第4小时观察到精液最大浓度与血浆水平相比(NIM为31.73±2.34%;OH - NIM为31.87±8.66%)。20例(66%)患者的排尿困难症状得到缓解。经直肠超声评估发现16例(54%)患者的炎症体征明显改善。整个样本中精子数量和活力未观察到统计学上的显著变化,而异常形态的数量显著减少。从这些结果来看,尼美舒利似乎是一种有效的抗炎药,在生殖器官中具有良好的扩散性且副作用低。